Shares of biotech company Ziopharm Oncology (ZIOP +5.86%) were up more than 17% today, after the company announced that its phase 3 clinical trial for its experimental cancer drug palifosfamide reached enough progression-free survival events to initiate data collection and the statistical analysis of the study. With top-line results -- a major binary event for Ziopharm investors -- to be revealed in late March, health-care analyst Max Macaluso discusses today's stock-price surge and what Ziopharm investors need to watch.
1 Upcoming Catalyst for Ziopharm
By Max Macaluso – Feb 12, 2013 at 6:30PM
NASDAQ: TCRT
Alaunos Therapeutics
Market Cap
$5.6M
Today's Change
(5.86%) $0.15
Current Price
$2.71
Price as of October 23, 2025 at 4:00 PM ET
Why did this stock soar today?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo